Market cap
$26.8bn
Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.
Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.
We have financed our operations primarily through the public offerings of our equity securities, debt financings and revenue interest financings. The following table summarizes revenue by product and geography for the three months ended June 30, 2026 and 2025 (in thousands): Product revenues, net, for the three months ended June 30, 2026 were $425.5 million as compared to $107.4 million for the same period in 2025, an increase of $318.1 million, or 296%. This increase was a result of $308.6 million of US commercial sales of BRINSUPRI following approval in August 2025 and an $8.9 million growth in sales of ARIKAYCE, primarily driven by growth in international sales. …INSMED Inc, 10-Q, period ended 2026-06-30, filed 2026-08-06